CD82 anticorps (C-Term)

N° du produit ABIN500108

Détail du produit anti-CD82 anticorps

Antigène: CD82

Épitope: C-Term

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CD82 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Specificité: This antibody detects CD82 at C-term.

Réactivité croisée (Details): Species reactivity (tested):Human, Mouse

Purification: Peptide affinity chromatography

Immunogène: KAI1 antibody was raised against a 15 amino acid peptide from near the carboxy terminus of human KAI1.

Isotype: IgG

Information d'application

Indications d'application: ELISA. Western blot: 0.5 - 1 μg/mL. Immunohistochemistry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Buffer: PBS containing 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Détails sur CD82

Antigène: CD82

Autre désignation: CD82 (CD82 Produits)

Synonymes: anticorps AA682076, anticorps AL023070, anticorps C33, anticorps IA4, anticorps Kai1, anticorps Tspan27, anticorps 4F9, anticorps GR15, anticorps KAI1, anticorps R2, anticorps SAR2, anticorps ST6, anticorps TSPAN27, anticorps CD82 antigen, anticorps CD82 molecule, anticorps Cd82 molecule, anticorps Cd82, anticorps CD82

Sujet: KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene. This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression. The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients. Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen. It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases. At least two isoforms of KAI1 are known to exist.Synonyms: C33 antigen, IA4, Inducible membrane protein R2, KAI1, Kangai-1, Metastasis suppressor Kangai-1, SAR2, ST6, Suppressor of tumorigenicity protein 6, TSPAN27, Tetraspanin-27

ID gène: 3732

NCBI Accession: NP_002222

UniProt: P27701

Pathways: Signalisation p53